Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Recursion Pharmaceuticals Inc Cl A (RXRX)

Recursion Pharmaceuticals Inc Cl A (RXRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,374,731
  • Shares Outstanding, K 170,774
  • Annual Sales, $ 10,180 K
  • Annual Income, $ -186,480 K
  • 60-Month Beta 0.20
  • Price/Sales 135.57
  • Price/Cash Flow N/A
  • Price/Book 2.80
Trade RXRX with:

Options Overview Details

View History
  • Implied Volatility 91.07% ( +5.32%)
  • Historical Volatility 104.53%
  • IV Percentile 32%
  • IV Rank 14.15%
  • IV High 212.59% on 03/04/22
  • IV Low 71.03% on 07/16/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 10
  • Volume Avg (30-Day) 82
  • Put/Call OI Ratio 1.37
  • Today's Open Interest 2,576
  • Open Int (30-Day) 3,103

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.35
  • Number of Estimates 2
  • High Estimate -0.33
  • Low Estimate -0.36
  • Prior Year -0.31
  • Growth Rate Est. (year over year) -12.90%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.53 +47.20%
on 06/13/22
9.40 -13.40%
on 06/24/22
+1.97 (+31.93%)
since 05/27/22
3-Month
4.92 +65.45%
on 05/12/22
9.40 -13.40%
on 06/24/22
+1.01 (+14.17%)
since 03/30/22
52-Week
4.92 +65.45%
on 05/12/22
42.81 -80.99%
on 07/13/21
-28.36 (-77.70%)
since 06/30/21

Most Recent Stories

More News
Recursion Announces Initiation of Phase 2/3 Trial for the Treatment of NF2-Mutated Meningiomas at Children's Tumor Foundation NF Conference

/PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced the...

RXRX : 8.14 (+1.12%)
3 Cathie Wood Stocks That Could Deliver Monster Returns

Here's why our roundtable likes 10x Genomics, Beam Therapeutics, and Recursion Pharmaceuticals.

TXG : 45.25 (-2.06%)
BEAM : 38.71 (-4.23%)
RXRX : 8.14 (+1.12%)
ILMN : 184.36 (-1.11%)
RHHBY : 41.7100 (-0.24%)
Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Misses Revenue Estimates

Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of -164.71% and 96.51%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?...

RXRX : 8.14 (+1.12%)
MEIP : 0.6050 (+0.83%)
IsoRay (ISR) Reports Q3 Loss, Lags Revenue Estimates

IsoRay (ISR) delivered earnings and revenue surprises of 0% and 7.62%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

ISR : 0.3090 (+6.92%)
RXRX : 8.14 (+1.12%)
Akebia Therapeutics (AKBA) Reports Q1 Loss, Tops Revenue Estimates

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -29.63% and 39.06%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

AKBA : 0.3531 (-7.15%)
RXRX : 8.14 (+1.12%)
Catalio Capital Management Raises $381 Million for Oversubscribed Third Life Sciences Fund

Catalio Capital Management, LP (“Catalio”), a leading multi-strategy life sciences investment firm, today announced the successful close of its third venture fund, Catalio Nexus Fund III (“Fund III”...

RXRX : 8.14 (+1.12%)
CMPS : 10.82 (+4.44%)
ATAI : 3.64 (-1.09%)
EXAS : 39.37 (-2.98%)
LH : 234.36 (-2.35%)
Recursion (RXRX) Inks Neuroscience and Oncology Deal With Roche

Recursion (RXRX) inks a collaboration with Roche to identify novel targets and advance medicines in areas of neuroscience and oncology indication. Shares rise.

RHHBY : 41.7100 (-0.24%)
ENDP : 0.4600 (-11.98%)
BAYRY : 14.8500 (-1.13%)
RXRX : 8.14 (+1.12%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science and engineering. Recursion Pharmaceuticals Inc. is based in SALT LAKE CITY.

See More

Key Turning Points

3rd Resistance Point 8.62
2nd Resistance Point 8.45
1st Resistance Point 8.25
Last Price 8.14
1st Support Level 7.88
2nd Support Level 7.71
3rd Support Level 7.51

See More

52-Week High 42.81
Fibonacci 61.8% 28.34
Fibonacci 50% 23.87
Fibonacci 38.2% 19.39
Last Price 8.14
52-Week Low 4.92

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar